Retension Pharmaceuticals Secures $10.4M Series A to Advance Phase 2 Hypertension Study
Key Highlights $10.4 million Series A funding secured to advance RTN-001 for hypertension treatment. RTN-001 targets patients with uncontrolled…
Browsing Tag
Dr. Paul Sweetnam
1 post